Navigation Links
Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
Date:8/29/2008

CRANBURY, N.J., Aug. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced Chief Operating Officer Matthew Patterson will make a presentation at the BioCentury NewsMakers in the Biotech Industry Conference on Thursday, September 4, 2008 at 2:30 p.m. EDT in Room 402/403 with a breakout session immediately following the presentation in Room 401. The conference will be held at Millennium Broadway Hotel & Conference Center in New York.

A webcast and audio archive of the presentation will be available at http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 30 days until October 4, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
2. Amicus Therapeutics Announces First Quarter 2008 Financial Results
3. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
5. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
9. Amicus Therapeutics to Host R&D Day
10. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Salt Lake City, Utah (PRWEB) August 27, 2014 ... new construction that will expand its current Salt Lake ... operations currently underway outside of Utah to ultimately create ... the next 20 years. , “Utah is home ... many of whom can be credited with Varian’s success ...
(Date:8/27/2014)... 2014 In 2013, Lawrence ... Livermore National Security LLC (LLNS), was awarded ... a state-of-the-art laser system for the European Union's ... construction in the Czech Republic. , When commissioned ... called the " High repetition-rate Advanced Petawatt Laser ...
(Date:8/27/2014)... One of nature,s mysteries is how plants survive ... in the sun,s rays, while using this energy ... proteins in the plant,s blades quickly dissipate the ... protein quakes. Researchers at DTU Physics have now ... plants, algae and bacteria contain light-absorbing proteins which ...
(Date:8/27/2014)... DUBLIN , Aug. 27, 2014 ... of the "Global Lactic Acid  (Biodegradable Polymer, ... - Trends & Forecasts to 2019" report ... the simplest hydroxyl-carboxylic acid with an asymmetrical carbon ... in the biodegradable polymer, food and beverage, personal ...
Breaking Biology Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3DTU researchers film protein quake for the first time 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2
... Top,management today announced that it has signed a ... worldwide commercialization of,ZP1846, a GLP-2 (glucagon-like peptide-2) receptor ... diarrhea (CID), a debilitating,condition affecting patients undergoing cancer ... Under the terms of ...
... executive officer with Radiation Shield Technologies (RST), will introduce ... Society of North America (RSNA) 94th Scientific Assembly and ... 5 p.m. Nov. 30 to Dec. 5 at McCormick ... North Building, Hall B. Booth No.: 9517. A press ...
... Evalve, Inc., the leader in,the development of ... today that the first three patients have been ... of Hull, Castle Hill Hospital,in the United Kingdom. ... device which provides a non-surgical mitral valve repair,option ...
Cached Biology Technology:Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist 2Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist 3Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist 4Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist 5Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist 6 New Radiation-Blocking Medical Garments Introduced at RSNA Meeting in Chicago : Demron-M Technology Provides Total Protection in a Lightweight, Durable, Flexible Fabric 2First United Kingdom Patients Treated With Percutaneous MitraClip(R) System 2First United Kingdom Patients Treated With Percutaneous MitraClip(R) System 3
(Date:8/28/2014)... identified a handful of bacterial culprits that may drive ... ulcerative colitis, using patients, own intestinal immune responses as ... in the journal Cell . , Trillions of ... a critical role in the development and progression of ... of bacterial species affect a person,s susceptibility to IBD ...
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced the ... Genetics from October 18 22, 2014 in San ... the entry of students, post doctorates and scientists from ... community and to encourage the participation of young scientists ... year MARC conferred 16 awards totaling $29,600., The FASEB ...
(Date:8/28/2014)... Ga. The support of peer groups and ... breastfeeding programs, according to recent University of Georgia ... in the Athens-Clarke County area determined that role ... outcomes of mothers of infants. , "Mothers who ... successful at breastfeeding," said study co-author Alex Anderson, ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2Breastfeeding study shows need for effective peer counseling programs 2
... The prediction of the structure and function of ... foremost importance in the field of structural biology. Since ... molecule that carries all genetic information) by Watson and ... that determines the evolution of the spatial arrangement of ...
... A new weight loss study conducted by Ben-Gurion University of the ... products lost more weight on average than those who consumed little ... also found participants with the highest dairy calcium intake, equal to ... dairy calcium), lost about 12 pounds (6 kg.) at the end ...
... PhD, associate professor and endowed chair in molecular signaling ... the UofL Department of Neurological Surgery, has received a ... fund a project that will aim to explain how ... someday help scientists develop better treatment strategies for illnesses ...
Cached Biology News:First observation of the folding of a nucleic acid 2Drink milk and lose more weight, according to Ben-Gurion University of the Negev research 2
NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
... Zero Blunt TOPO PCR ... is designed for cloning ... blunt-end PCR products. The ... TOPO Cloning and greater ...
... ULTROSPEC 6300 (YELLOW), 1 EA. ... the demanding requirements of the Pharmacopoeia in ... with the benefits of being able to ... of 1.0 nm and excellent scanning capability., ...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Biology Products: